Search

Your search keyword '"Stokroos, Robert J"' showing total 620 results
Start Over Author "Stokroos, Robert J"
620 results on '"Stokroos, Robert J"'

11. Sound Localization in Single-Sided Deafness; Outcomes of a Randomized Controlled Trial on the Comparison Between Cochlear Implantation, Bone Conduction Devices, and Contralateral Routing of Signals Hearing Aids.

Author

van Heteren, Jan A. A., van Oorschot, Hanneke D., Wendrich, Anne W., Peters, Jeroen P. M., Rhebergen, Koenraad S., Grolman, Wilko, Stokroos, Robert J., and Smit, Adriana L.

Subjects
HEARING disorder diagnosis, COCHLEAR implants, BONE conduction, SPEECH, RESEARCH funding, HEARING aids, STATISTICAL sampling, QUESTIONNAIRES, ACOUSTIC localization, TREATMENT effectiveness, RANDOMIZED controlled trials, DESCRIPTIVE statistics, LONGITUDINAL method, DEAFNESS, HEARING disorders, COMPARATIVE studies, HEARING, SPEECH perception, PEOPLE with disabilities, EQUIPMENT & supplies
Abstract

There is currently a lack of prospective studies comparing multiple treatment options for single-sided deafness (SSD) in terms of long-term sound localization outcomes. This randomized controlled trial (RCT) aims to compare the objective and subjective sound localization abilities of SSD patients treated with a cochlear implant (CI), a bone conduction device (BCD), a contralateral routing of signals (CROS) hearing aid, or no treatment after two years of follow-up. About 120 eligible patients were randomized to cochlear implantation or to a trial period with first a BCD on a headband, then a CROS (or vice versa). After the trial periods, participants opted for a surgically implanted BCD, a CROS, or no treatment. Sound localization accuracy (in three configurations, calculated as percentage correct and root-mean squared error in degrees) and subjective spatial hearing (subscale of the Speech, Spatial and Qualities of hearing (SSQ) questionnaire) were assessed at baseline and after 24 months of follow-up. At the start of follow-up, 28 participants were implanted with a CI, 25 with a BCD, 34 chose a CROS, and 26 opted for no treatment. Participants in the CI group showed better sound localization accuracy and subjective spatial hearing compared to participants in the BCD, CROS, and no-treatment groups at 24 months. Participants in the CI and CROS groups showed improved subjective spatial hearing at 24 months compared to baseline. To conclude, CI outperformed the BCD, CROS, and no-treatment groups in terms of sound localization accuracy and subjective spatial hearing in SSD patients. TRIAL REGISTRATION Netherlands Trial Register (https://onderzoekmetmensen.nl): NL4457, CINGLE trial. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Indication and efficacy of injection laryngoplasty for laryngeal clefts - A retrospective cohort study

Author

Zorgeenheid KNO Medisch, Zorgeenheid Kinderchirurgie Medisch, KNO Onderzoek, MS KNO, Brain, Child Health, van Stigt, Marit J.B., Coenraad, Saskia, Stegeman, Inge, Stokroos, Robert J., Tytgat, Stefaan H.A.J., Lindeboom, Maud Y.A., Bittermann, Arnold J.N., Zorgeenheid KNO Medisch, Zorgeenheid Kinderchirurgie Medisch, KNO Onderzoek, MS KNO, Brain, Child Health, van Stigt, Marit J.B., Coenraad, Saskia, Stegeman, Inge, Stokroos, Robert J., Tytgat, Stefaan H.A.J., Lindeboom, Maud Y.A., and Bittermann, Arnold J.N.

Published
2024

14. Head and Neck Paraganglioma (HNPGL) Registry: A study protocol for prospective data collection in patients with Head and Neck Paragangliomas

Author

Zorgeenheid Vaatchirurgie Medisch, Cancer, Genetica Klinische Genetica, MS Endocriene Oncologie, MS Radiologie, MS Radiotherapie, Zorgeenheid KNO Medisch, Brain, MS Hoofd-Hals Chirurgische Oncologie, Circulatory Health, Regenerative Medicine and Stem Cells, MS KNO, de Bresser, Carolijn J.M., van Nesselrooij, Bernadette P.M., van Treijen, Mark J.C., Braat, Arthur J.A.T., de Ridder, Mischa, Stokroos, Robert J., de Bree, Remco, de Borst, Gert J., Rijken, Johannes A., Petri, Bart Jeroen, Zorgeenheid Vaatchirurgie Medisch, Cancer, Genetica Klinische Genetica, MS Endocriene Oncologie, MS Radiologie, MS Radiotherapie, Zorgeenheid KNO Medisch, Brain, MS Hoofd-Hals Chirurgische Oncologie, Circulatory Health, Regenerative Medicine and Stem Cells, MS KNO, de Bresser, Carolijn J.M., van Nesselrooij, Bernadette P.M., van Treijen, Mark J.C., Braat, Arthur J.A.T., de Ridder, Mischa, Stokroos, Robert J., de Bree, Remco, de Borst, Gert J., Rijken, Johannes A., and Petri, Bart Jeroen

Published
2024

15. Tinnitus reduction in patients with single-sided deafness: the effect of cochlear implantation, bone conduction devices, and contralateral routing of sound hearing aids investigated in a randomized controlled trial

Author

Zorgeenheid KNO Medisch, MS KNO, Other research (not in main researchprogram), KNO Onderzoek, Brain, Wendrich, Anne W., Assouly, Kelly K.S., van Heteren, Jan A.A., Peters, Jeroen P.M., Grolman, Wilko, Stokroos, Robert J., Versnel, Huib, Smit, Adriana L., Zorgeenheid KNO Medisch, MS KNO, Other research (not in main researchprogram), KNO Onderzoek, Brain, Wendrich, Anne W., Assouly, Kelly K.S., van Heteren, Jan A.A., Peters, Jeroen P.M., Grolman, Wilko, Stokroos, Robert J., Versnel, Huib, and Smit, Adriana L.

Published
2024

16. The cost evaluation of day-case compared to inpatient cochlear implantation in adults: subanalysis of a randomized controlled trial

Author

Zorgeenheid KNO Medisch, MS KNO, Brain, Other research (not in main researchprogram), Bijzondere Formatie, MS Hoofd-Hals Chirurgische Oncologie, Derks, Laura S.M., Smit, Adriana L., Thomeer, Hans G.X.M., Grolman, Wilko, Stokroos, Robert J., Wegner, Inge, Zorgeenheid KNO Medisch, MS KNO, Brain, Other research (not in main researchprogram), Bijzondere Formatie, MS Hoofd-Hals Chirurgische Oncologie, Derks, Laura S.M., Smit, Adriana L., Thomeer, Hans G.X.M., Grolman, Wilko, Stokroos, Robert J., and Wegner, Inge

Published
2024

17. International perspective of injection laryngoplasty for laryngeal cleft – A survey study

Author

Zorgeenheid KNO Medisch, Zorgeenheid Kinderchirurgie Medisch, KNO Onderzoek, MS KNO, Brain, Child Health, van Stigt, Marit J.B., Coenraad, Saskia, Stegeman, Inge, Stokroos, Robert J., Tytgat, Stefaan H.A.J., Lindeboom, Maud Y.A., Bittermann, Arnold J.N., Zorgeenheid KNO Medisch, Zorgeenheid Kinderchirurgie Medisch, KNO Onderzoek, MS KNO, Brain, Child Health, van Stigt, Marit J.B., Coenraad, Saskia, Stegeman, Inge, Stokroos, Robert J., Tytgat, Stefaan H.A.J., Lindeboom, Maud Y.A., and Bittermann, Arnold J.N.

Published
2024

18. The effect of piston diameter in primary stapes surgery on surgical success

Author

MS KNO, Zorgeenheid KNO Medisch, Brain, MS Hoofd-Hals Chirurgische Oncologie, Blijleven, Esther E, Jellema, Maaike, Stokroos, Robert J, Wegner, Inge, Thomeer, Hans G X M, MS KNO, Zorgeenheid KNO Medisch, Brain, MS Hoofd-Hals Chirurgische Oncologie, Blijleven, Esther E, Jellema, Maaike, Stokroos, Robert J, Wegner, Inge, and Thomeer, Hans G X M

Published
2024

19. Quality of life, hearing results, patient satisfaction and postoperative complications of day-case versus inpatient unilateral cochlear implantation in adults: a randomized controlled, equivalence trial

Author

Zorgeenheid KNO Medisch, MS KNO, Brain, Other research (not in main researchprogram), Bijzondere Formatie, MS Hoofd-Hals Chirurgische Oncologie, Derks, Laura S.M., Smit, Adriana L., Thomeer, Hans G.X.M., Topsakal, Vedat, Grolman, Wilko, Stokroos, Robert J., Wegner, Inge, Zorgeenheid KNO Medisch, MS KNO, Brain, Other research (not in main researchprogram), Bijzondere Formatie, MS Hoofd-Hals Chirurgische Oncologie, Derks, Laura S.M., Smit, Adriana L., Thomeer, Hans G.X.M., Topsakal, Vedat, Grolman, Wilko, Stokroos, Robert J., and Wegner, Inge

Published
2024

20. Canal-wall up cholesteatoma surgery with mastoid obliteration leads to lower rates of disease recurrence without affecting hearing outcomes

Author

MS KNO, Brain, Other research (not in main researchprogram), Zorgeenheid KNO Medisch, Erfurt, Chiara, Westerhout, Sanne F, Straatman, Louise V, Smit, Adriana L, Stokroos, Robert J, Thomeer, Hans G X M, MS KNO, Brain, Other research (not in main researchprogram), Zorgeenheid KNO Medisch, Erfurt, Chiara, Westerhout, Sanne F, Straatman, Louise V, Smit, Adriana L, Stokroos, Robert J, and Thomeer, Hans G X M

Published
2024

21. Tinnitus reduction in patients with single-sided deafness: the effect of cochlear implantation, bone conduction devices, and contralateral routing of sound hearing aids investigated in a randomized controlled trial.

Author

Wendrich, Anne W., Assouly, Kelly K. S., van Heteren, Jan A. A., Peters, Jeroen P. M., Grolman, Wilko, Stokroos, Robert J., Versnel, Huib, and Smit, Adriana L.

Subjects
HEARING disorders, BONE conduction, HEARING aids, VISUAL analog scale, TINNITUS, COCHLEAR implants
Abstract

Objectives: Single-sided deafness (SSD) is often accompanied by tinnitus, resulting in a decreased quality of life. Currently, there is a lack of high level of evidence studies comparing different treatment options for SSD regarding tinnitus reduction. This randomized controlled trial (RCT) evaluated the effect of a cochlear implant (CI), bone conduction device (BCD), contralateral routing of sound (CROS), and no treatment on tinnitus outcomes in SSD patients, with follow-up extending to 24 months. Methods: A total of 120 adult SSD patients were randomized to three groups: CI, a trial period with first a BCD on a headband, then a CROS, or vice versa. After the trial periods, patients opted for a BCD, CROS, or no treatment. At the start of follow-up, 28 patients were implanted with a CI, 25 patients with a BCD, 34 patients had a CROS, and 26 patients chose no treatment. The Tinnitus Handicap Inventory (THI), Tinnitus Questionnaire (TQ), the Visual Analog Scale (VAS), and the Hospital Anxiety and Depression Scale (HADS) were completed at baseline and at 3, 6, 12, and 24 months of follow-up. Results: The CI and BCD groups showed significantly decreased tinnitus impact scores. The CI group showed the largest decrease, which was already observed at 3 months of follow-up. Compared to the baseline, the median THI score decreased by 23 points, the TQ score by 17 points, and the VAS score by 60 points at 24 months. In the BCD group, the TQ score decreased by 9 points, and the VAS decreased by 25 points at 24 months. The HADS anxiety and depression subscale showed no indication for anxiety or depression at baseline, nor at 24 months, for all groups. Conclusion: In this RCT, SSD patients treated with a CI or BCD showed an overall decrease in tinnitus impact scores up to 24 months compared to baseline. The CI group reported a stable and the largest reduction. Cochlear implants appear to be superior to BCD and CROS, and no treatment for achieving partial or complete resolution of tinnitus in patients with SSD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Head and Neck Paraganglioma (HNPGL) Registry: A study protocol for prospective data collection in patients with Head and Neck Paragangliomas.

Author

de Bresser, Carolijn J. M., van Nesselrooij, Bernadette P. M., van Treijen, Mark J. C., Braat, Arthur J. A. T., de Ridder, Mischa, Stokroos, Robert J., de Bree, Remco, de Borst, Gert J., Rijken, Johannes A., and Petri, Bart-Jeroen

Subjects
PATIENT reported outcome measures, PARAGANGLIOMA, RESEARCH protocols, ACADEMIC medical centers
Abstract

Introduction: There is a lack of comprehensive and uniform data on head and neck paragangliomas (HNPGLs), and research is challenging due to its rarity and the involvement of multiple medical specialties. To improve current research data collection, we initiated the Head and Neck Paraganglioma Registry (HNPGL Registry). The aim of the HNPGL Registry is to a) collect extensive data on all HNPGL patients through a predefined protocol, b) give insight in the long term outcomes using patient reported outcome measures (PROMs), c) create uniformity in the diagnostic and clinical management of these conditions, and thereby d) help provide content for future (randomized) research. Methods and analysis: The HNPGL Registry is designed as a prospective longitudinal observational registry for data collection on HNPGL patients and carriers of (likely) pathogenic variants causative of HNPGLs. All patients, regardless of the received treatment modality, can be included in the registry after informed consent is obtained. All relevant data regarding the initial presentation, diagnostics, treatment, and follow-up will be collected prospectively in an electronic case report form. In addition a survey containing the EuroQol 5D-5L (EQ-5D-5L), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Modified Fatigue Impact Scale (MFIS), Short QUestionnaire to Assess Health-enhancing physical activity (SQUASH), Cancer Worry Scale (CWS) and Hospital Anxiety and Depression Scale (HADS) will be sent periodically. The registry protocol was approved by the Medical Ethical Review Board of the University Medical Center Utrecht. Conclusion: The HNPGL Registry data will be used to further establish the optimal management for HNPGL patients and lay the foundation for guideline recommendations and the outline of future research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Upper Airway Stimulation in Patients with Obstructive Sleep Apnea:Long-Term Surgical Success, Respiratory Outcomes, and Patient Experience

Author

Veugen, Christianne C. A. F. M., Dieleman, Eveline, Hardeman, Johannes A., Stokroos, Robert J., Copper, Marcel P., Veugen, Christianne C. A. F. M., Dieleman, Eveline, Hardeman, Johannes A., Stokroos, Robert J., and Copper, Marcel P.

Abstract

Introduction Upper airway stimulation (UAS) with electric activation of the hypoglossal nerve has emerged as a promising treatment for patients with moderate-to-severe obstructive sleep apnea. Objective To retrospectively analyze objective and subjective outcome measures after long-term follow-up in obstructive sleep apnea patients receiving upper airway stimulation. Methods An observational retrospective single-center cohort study including a consecutive series of patients diagnosed with obstructive sleep apnea receiving upper airway stimulation. Results Twenty-five patients were included. The total median apnea-hypopnea index (AHI) significantly decreased from 37.4 to 8.7 events per hour at the 12-month followup (p < 0.001). The surgical success rate was 96%. Adverse events were reported by 28% of the patients. Conclusion Upper airway stimulation is an effective and safe treatment for obstructive sleep apnea in patients with continuous positive airway pressure (CPAP) failure or intolerance. However, it is possible that the existing in and exclusion criteria for UAS therapy in the Netherlands have positively influenced our results.

Published
2023

38. Correction : Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial

Author

Schepens, Emma J.A., Blijleven, Esther E., Boek, Wilbert M., Boesveldt, Sanne, Stokroos, Robert J., Stegeman, Inge, Kamalski, Digna M.A., Schepens, Emma J.A., Blijleven, Esther E., Boek, Wilbert M., Boesveldt, Sanne, Stokroos, Robert J., Stegeman, Inge, and Kamalski, Digna M.A.

Abstract

The original article [1] contained the following errors with their respective amendments: 1) Abstract, lines 48 and 49: “Median TDI score on SST was 26.8 (IQR 23.6-29.3) in the placebo group and 28.8 (IQR 24.0-30.9) in the prednisolone group, with a median difference of 2.0 (95% CI 0.75 to 1.5).” to “Median TDI score on SST was 26.8 (IQR 23.6-29.3) in the placebo group and 28.8 (IQR 24.0-30.9) in the prednisolone group, with a median difference of - 1.5 (-3.0 to 0.25).” 2) Outcome, line 233-235: “Median TDI score was 26.8 (IQR 23.6- 29.3) in the placebo group and 28.8 (IQR 24.0- 30.9) in the prednisolone group, with a median difference of 2.0 (95% CI 0.75 to 1.5, p = 0.10).” to “Median TDI score was 26.8 (IQR 23.6- 29.3) in the placebo group and 28.8 (IQR 24.0- 30.9) in the prednisolone group, with a median difference of - 1.5 (-3.0 to 0.25).” 3) Line 237-238: "Self-reported smell function on VAS-score was 3.2 (IQR 1.8- 6.5) in the placebo group and 3.6 (IQR 1.0- 5.8) in the prednisolone group with a median difference of 0.45 (95% CI 1.1 to -1.2, p = 0.53)." to "Self-reported smell function on VAS-score was 3.2 (IQR 1.8- 6.5) in the placebo group and 3.6 (IQR 1.0- 5.8) in the prednisolone group with a median difference of 0.3 (95% CI -0.9 to -1.3, p = 0.53)." 4) Line 240-242: “Self-reported taste function on VAS-score was 5.6 (IQR 2.3- 7.6) in the placebo group and 5.0 (IQR 2.0- 7.8) in the prednisolone group with a median difference of 0.25 (95% CI 0.1 to -0.2, p = 0.80).” to “Self-reported taste function on VAS-score was 5.6 (IQR 2.3- 7.6) in the placebo group and 5.0 (IQR 2.0- 7.8) in the prednisolone group with a median difference of 0.1 (95% CI -1.0 to 1.3, p = 0.80)”.

Published
2023

40. The impact of tinnitus on adult cochlear implant recipients: A mixed-method approach

Author

KNO Onderzoek, Zorgeenheid KNO Medisch, Brain, MS KNO, Other research (not in main researchprogram), Assouly, Kelly K S, Shabbir, Maryam, van Dijk, Bas, Hoare, Derek J, Akeroyd, Michael A, Stokroos, Robert J, Stegeman, Inge, Smit, Adriana L, KNO Onderzoek, Zorgeenheid KNO Medisch, Brain, MS KNO, Other research (not in main researchprogram), Assouly, Kelly K S, Shabbir, Maryam, van Dijk, Bas, Hoare, Derek J, Akeroyd, Michael A, Stokroos, Robert J, Stegeman, Inge, and Smit, Adriana L

Published
2023

41. Development and internal validation of a prediction model for the presence of tinnitus in a Dutch population-based cohort

Author

MS KNO, Brain, Other research (not in main researchprogram), Zorgeenheid KNO Medisch, Epi Methoden Team 3, Infection & Immunity, Rademaker, Maaike M, Smit, Adriana L, Stokroos, Robert J, van Smeden, Maarten, Stegeman, Inge, MS KNO, Brain, Other research (not in main researchprogram), Zorgeenheid KNO Medisch, Epi Methoden Team 3, Infection & Immunity, Rademaker, Maaike M, Smit, Adriana L, Stokroos, Robert J, van Smeden, Maarten, and Stegeman, Inge

Published
2023

42. Health Economic Cost Analysis for Percutaneous Bone Conduction Devices: The Minimally Invasive Ponto Surgery Versus Linear Incision Technique with Tissue Preservation

Author

MS KNO, Brain, Zorgeenheid KNO Medisch, Strijbos, Ruben M, Straatman, Louise V, Stegeman, Inge, Holmberg, Marcus, Johansson, Martin L, Stokroos, Robert J, MS KNO, Brain, Zorgeenheid KNO Medisch, Strijbos, Ruben M, Straatman, Louise V, Stegeman, Inge, Holmberg, Marcus, Johansson, Martin L, and Stokroos, Robert J

Published
2023

44. Systematic review: Validity, reliability, and diagnostic accuracy of the electrogustometer

Author

MS KNO, Zorgeenheid KNO Medisch, Brain, MS Hoofd-Hals Chirurgische Oncologie, Blijleven, Esther E, Fuchten, Denise, Dullaart, Max J, Stokroos, Robert J, Thomeer, Henricus G X M, Wegner, Inge, MS KNO, Zorgeenheid KNO Medisch, Brain, MS Hoofd-Hals Chirurgische Oncologie, Blijleven, Esther E, Fuchten, Denise, Dullaart, Max J, Stokroos, Robert J, Thomeer, Henricus G X M, and Wegner, Inge

Published
2023

46. The impact of injury of the chorda tympani nerve during primary stapes surgery or cochlear implantation on taste function, quality of life and food preferences: A study protocol for a double-blind prospective prognostic association study

Author

MS KNO, MS Hoofd-Hals Chirurgische Oncologie, KNO Onderzoek, Zorgeenheid KNO Medisch, Brain, Blijleven, Esther E., Wegner, Inge, Stokroos, Robert J., Thomeer, Hans G.X.M., MS KNO, MS Hoofd-Hals Chirurgische Oncologie, KNO Onderzoek, Zorgeenheid KNO Medisch, Brain, Blijleven, Esther E., Wegner, Inge, Stokroos, Robert J., and Thomeer, Hans G.X.M.

Published
2023

47. Choice of treatment evaluated after trial periods with bone conduction devices and contralateral routing of sound systems in patients with single-sided deafness

Author

MS KNO, Other research (not in main researchprogram), Zorgeenheid KNO Medisch, Brain, KNO Onderzoek, Wendrich, Anne W, van Heteren, Jan A A, Peters, Jeroen P M, Cattani, Guido, Stokroos, Robert J, Versnel, Huib, Smit, Adriana L, MS KNO, Other research (not in main researchprogram), Zorgeenheid KNO Medisch, Brain, KNO Onderzoek, Wendrich, Anne W, van Heteren, Jan A A, Peters, Jeroen P M, Cattani, Guido, Stokroos, Robert J, Versnel, Huib, and Smit, Adriana L

Published
2023

48. Correction: Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial (BMC Medicine, (2022), 20, 1, (445), 10.1186/s12916-022-02625-5)

Author

MS KNO, Zorgeenheid KNO Medisch, Brain, Schepens, Emma J.A., Blijleven, Esther E., Boek, Wilbert M., Boesveldt, Sanne, Stokroos, Robert J., Stegeman, Inge, Kamalski, Digna M.A., MS KNO, Zorgeenheid KNO Medisch, Brain, Schepens, Emma J.A., Blijleven, Esther E., Boek, Wilbert M., Boesveldt, Sanne, Stokroos, Robert J., Stegeman, Inge, and Kamalski, Digna M.A.

Published
2023

49. One-year psychophysical evaluation of COVID-19-induced olfactory disorders : a prospective cohort study

Author

Schepens, Emma J.A., Boek, Wilbert M., Boesveldt, Sanne, Stokroos, Robert J., Stegeman, Inge, Kamalski, Digna M.A., Schepens, Emma J.A., Boek, Wilbert M., Boesveldt, Sanne, Stokroos, Robert J., Stegeman, Inge, and Kamalski, Digna M.A.

Abstract

Background: Olfactory disorders are common in COVID-19. While many patients recover within weeks, a notable number of patients suffer from prolonged olfactory disorders. Much research has focused on the acute phase of olfactory disorders in COVID-19; however, there is still inconsistency regarding the prognosis. We aim to assess both objective and subjective olfactory function in patients with persisting olfactory disorders following COVID-19, 1 year after diagnosis. Methods: We objectively measured olfactory function in 77 patients who initially had COVID-19-induced smell disorders, 1 year after confirmed diagnosis. These patients previously underwent two objective measurements at approximately 3 and 6 months after COVID-19, in the context of the COCOS trial (COrticosteroids for COvid-19-induced loss of Smell). The main outcome measurement was TDI score (threshold-discrimination-identification) on Sniffin’ Sticks Test (SST). Secondary outcomes included objective gustatory function on Taste Strip Test (TST), self-reported olfactory, gustatory and trigeminal function on a visual analogue scale (VAS) and outcomes on questionnaires about quality of life, and nasal symptoms. Results: The findings of this study show that 1 year following COVID-19, the median TDI score increased to 30.75 (IQR 27.38–33.5), regarded as normosmia. The median TDI score started at 21.25 (IQR 18.25–24.75) at baseline and increased to 27.5 (IQR 23.63–30.0) at 6 months following COVID-19. The increase of 9.5 points on the TDI score between baseline and 1 year after COVID-19 marks a clinically relevant improvement. Regarding the self-reported VAS score (1–10) on sense of smell, it increased from 1.2 (IQR 0.4–3.0) at baseline to 3.2 (IQR 1.4–6.0) at 6 months and further improved up to 6.1 (IQR 2.7–7.5) after 1 year. Objective gustatory function increased with 2 points on TST a year after diagnosis. Self-reported olfactory, gustatory, and trigeminal functions also improved over time, as did quality

Published
2023

50. Upper Airway Stimulation in Patients with Obstructive Sleep Apnea: Long-Term Surgical Success, Respiratory Outcomes, and Patient Experience

Author

Zorgeenheid KNO Medisch, UMC Utrecht Holding, KNO Onderzoek, Brain, Veugen, Christianne C.A.F.M., Dieleman, Eveline, Hardeman, Johannes A., Stokroos, Robert J., Copper, Marcel P., Zorgeenheid KNO Medisch, UMC Utrecht Holding, KNO Onderzoek, Brain, Veugen, Christianne C.A.F.M., Dieleman, Eveline, Hardeman, Johannes A., Stokroos, Robert J., and Copper, Marcel P.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results